赛诺菲喜保宁是什么药物？

Sanofi is not currently on the market in China, but many parents of children with infantile spasms purchase it through various channels. Next, let’s take a look at what kind of drug Sanofi Vigabatrin is.

Sanofi Vigabatrin (vigabatrin) was approved for marketing in the UK in 1989 and was approved by the US Food and Drug Administration in 2009 for the treatment of infantile spasms and refractory focal epilepsy, making it one of the first-choice drugs for the treatment of infantile spasms, especially in patients with tuberous sclerosis. Vigabatrin is a structural analog of gamma-aminobutyric acid (GABA). It inhibits the catabolism of GABA by irreversibly inhibiting GABA transaminase, thereby increasing the concentration of GABA in the brain and achieving anti-epileptic therapeutic effects.

Sanofi Vigabatrin has an anti-epileptic effect and has a certain auxiliary therapeutic effect in the treatment of epilepsy. It is especially useful for patients who have failed to respond to other anti-epileptic drugs or for patients with partial seizures and infantile spasms. When used alone, it has a good effect on newly diagnosed patients, but it should not be used by pregnant or lactating women, and it should also be used with caution by the elderly or patients with renal damage.

Developed by Sanofi, the French Sanofi-Aventis Group (Sanofi) is the third largest pharmaceutical company in the world and ranks first in Europe. Its business covers more than 100 countries around the world, and currently has approximately 11,000 scientists and 100,000 employees serving the health industry. Relying on a world-class research and development organization to develop innovative treatment solutions, Sanofi-Aventis is a leader in seven therapeutic areas: cardiovascular disease and thrombosis, oncology, diabetes and central nervous system, internal medicine and vaccines.

Recommended related hot articles: /newsDetail/95649.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.